The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study.
Bottom Line: A higher proportion of SU-treated patients experienced adverse events (AEs) compared with vildagliptin (22.8% vs. 10.2%).In this real-world study of fasting Muslim patients with T2DM, vildagliptin was associated with significantly fewer hypoglycaemic episodes compared with SU therapy.Vildagliptin was well tolerated in this patient population.
Affiliation: Dasman Diabetes Institute, Kuwait, Kuwait.Show MeSH
Related in: MedlinePlus
Mentions: At the end of the study, the mean change in HbA1c from prefasting baseline levels was –0.24% in the vildagliptin group compared with +0.02% in the SU group (–0.26% between-treatment difference; p < 0.001) (Figure 2). Furthermore, weight changes pre- to post-Ramadan were –0.76 kg with vildagliptin compared with –0.13 kg with SUs, representing a mean between-treatment difference of –0.63 kg (p < 0.001) (Figure 3).